Orthocell (ASX:OCC) said the first surgical use of its nerve repair product Remplir in the US was completed, and it expects a ramp-up in US sales in the first half of fiscal year 2026, according to a Wednesday Australian bourse filing.
It said key workstreams required for the US commercialization of the product are all progressing. Its initial focus is on the East Coast market, and it has appointed 14 specialist distributors, covering 25 states.
Its shares fell 1% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。